The treatment strategy for people with classical Hodgkin lymphoma has changed with the introduction of brentuximab vedotin (BV), a CD30-directed antibody-drug combination.
The treatment strategy for people with classical Hodgkin lymphoma has changed with the introduction of brentuximab vedotin (BV), a CD30-directed antibody-drug combination.
